Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Seranova Bio, Inc. is at the forefront of biotechnology research, specializing in the development of next-generation senolytic antibody therapeutics. The company's pioneering approach focuses on identifying and targeting senescent cells—cells that contribute to aging and various age-related pathologies. By developing therapies to selectively eliminate these cells, Seranova Bio aims to offer novel treatments for a range of conditions associated with aging, potentially improving healthspan and quality of life. They are currently in the preclinical stage, advancing their innovative science towards clinical applications.
Central hub for research and development, strategic planning, and corporate operations, focusing on advancing their senolytic antibody pipeline.
Located within the Cambridge Innovation Center (CIC), providing access to state-of-the-art laboratory facilities, collaborative office spaces, and a dynamic ecosystem of startups and established biotech companies.
Expected to be a dynamic, science-driven, and collaborative environment, typical of early-stage biotech companies, with a strong focus on innovation, rapid iteration, and achieving research milestones.
Strategically located in Cambridge, MA, one of the world's leading biotechnology clusters, providing unparalleled access to top scientific talent, renowned research institutions, venture capital, and potential industry collaborators.
As a preclinical stage biotechnology company based in Cambridge, MA, Seranova Bio's primary operational footprint is concentrated in the United States. While their research into age-related diseases has global relevance and they may engage in international collaborations or plan for global clinical trials in the future, their current physical presence and direct operational support are focused domestically. Their strategic location in a global biotech hub, however, connects them to international scientific and investment communities.
245 Main St
Cambridge
MA
USA
Address: N/A
All core functions, including research, development, and corporate strategy, are managed from the Cambridge headquarters to ensure close collaboration and efficient resource allocation during the critical early stages of development.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Seranova Bio' leadership includes:
Seranova Bio has been backed by several prominent investors over the years, including:
Seranova Bio, founded in 2021, is led by its co-founders. In the last 12 months, there have been no public announcements of new executive hires joining the C-suite or departures from the core founding executive team, indicating leadership stability as the company focuses on its preclinical development milestones.
Discover the tools Seranova Bio uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Based on common patterns for biotechnology companies of its size and stage, Seranova Bio likely utilizes standard professional email formats. The most probable formats include first initial followed by last name, or first name separated by a dot from the last name, at their company domain.
[first_initial][last]@seranovabio.com (e.g., aglobig@seranovabio.com) or [first].[last]@seranovabio.com (e.g., anna.globig@seranovabio.com)
Format
aglobig@seranovabio.com
Example
80%
Success rate
PR Newswire • October 26, 2023
Seranova Bio announced the successful closing of a $7 million seed funding round. The financing was led by K5 Global and included participation from Threshold Ventures, Good Growth Capital, Gaingels, Bioverge, and existing investors. The funds are designated to advance the company's pipeline of senolytic antibody therapeutics targeting senescent cells to treat age-related diseases....more
Fierce Biotech • October 26, 2023
Fierce Biotech reported on Seranova Bio's $7 million seed funding. The article highlights the company's focus on developing antibody-based treatments to clear senescent cells, a novel approach in the field of age-related diseases. The funding round, led by K5 Global, aims to propel their preclinical candidates forward....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Seranova Bio, are just a search away.